Cited 3 times in
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.